Performance of plasma biomarkers for diagnosis and prediction of dementia in a Brazilian cohort

IF 14.7 1区综合性期刊 Q1 MULTIDISCIPLINARY SCIENCES Nature Communications Pub Date : 2025-03-25 DOI:10.1038/s41467-025-56756-3

Luis E. Santos, Paulo Mattos, Thais L. Pinheiro, Ananssa Silva, Claudia Drummond, Felipe Kenji Sudo, Fernanda Barros-Aragão, Bart Vanderborght, Carlos Otávio Brandão, Sergio T. Ferreira, Fernanda Tovar-Moll, Fernanda G. De Felice

{"title":"Performance of plasma biomarkers for diagnosis and prediction of dementia in a Brazilian cohort","authors":"Luis E. Santos, Paulo Mattos, Thais L. Pinheiro, Ananssa Silva, Claudia Drummond, Felipe Kenji Sudo, Fernanda Barros-Aragão, Bart Vanderborght, Carlos Otávio Brandão, Sergio T. Ferreira, Fernanda Tovar-Moll, Fernanda G. De Felice","doi":"10.1038/s41467-025-56756-3","DOIUrl":null,"url":null,"abstract":"Despite remarkable progress in the biomarker field in recent years, local validation of plasma biomarkers of Alzheimer’s disease (AD) and dementia is still lacking in Latin America. In this longitudinal cohort study of 145 elderly Brazilians, we assess the diagnostic performance of plasma biomarkers, based on clinical diagnosis and CSF biomarker positivity. Follow-up data of up to 4.7 years were used to determine performance in predicting diagnostic conversions. Participants were clinically categorized as cognitively unimpaired (n = 49), amnestic mild cognitive impairment (n = 29), AD (n = 38), Lewy body dementia (n = 22), or vascular dementia (n = 7). Plasma Tau, Aβ40, Aβ42, NfL, GFAP, pTau231, pTau181 and pTau217 were measured on the SIMOA HD-X platform. Plasma pTau217 showed excellent performance determining CSF biomarker status in the cohort, either alone (ROC AUC = 0.94, 95% CI: [0.88–1.00]) or as a ratio to Aβ42 (ROC AUC = 0.98, 95% CI: [0.94–1.00]). This study comprises an initial step towards local validation and adoption of dementia biomarkers in Brazil.","PeriodicalId":19066,"journal":{"name":"Nature Communications","volume":"41 1","pages":""},"PeriodicalIF":14.7000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Communications","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.1038/s41467-025-56756-3","RegionNum":1,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Despite remarkable progress in the biomarker field in recent years, local validation of plasma biomarkers of Alzheimer’s disease (AD) and dementia is still lacking in Latin America. In this longitudinal cohort study of 145 elderly Brazilians, we assess the diagnostic performance of plasma biomarkers, based on clinical diagnosis and CSF biomarker positivity. Follow-up data of up to 4.7 years were used to determine performance in predicting diagnostic conversions. Participants were clinically categorized as cognitively unimpaired (n = 49), amnestic mild cognitive impairment (n = 29), AD (n = 38), Lewy body dementia (n = 22), or vascular dementia (n = 7). Plasma Tau, Aβ₄₀, Aβ₄₂, NfL, GFAP, pTau231, pTau181 and pTau217 were measured on the SIMOA HD-X platform. Plasma pTau217 showed excellent performance determining CSF biomarker status in the cohort, either alone (ROC AUC = 0.94, 95% CI: [0.88–1.00]) or as a ratio to Aβ₄₂ (ROC AUC = 0.98, 95% CI: [0.94–1.00]). This study comprises an initial step towards local validation and adoption of dementia biomarkers in Brazil.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

尽管近年来生物标记物领域取得了令人瞩目的进展，但在拉丁美洲仍缺乏对阿尔茨海默病（AD）和痴呆症血浆生物标记物的本地验证。在这项针对 145 名巴西老年人的纵向队列研究中，我们根据临床诊断和脑脊液生物标志物阳性率评估了血浆生物标志物的诊断性能。长达 4.7 年的随访数据用于确定预测诊断转换的性能。参与者在临床上被分为认知功能未受损（49 人）、失忆性轻度认知障碍（29 人）、AD（38 人）、路易体痴呆（22 人）或血管性痴呆（7 人）。血浆Tau、Aβ40、Aβ42、NfL、GFAP、pTau231、pTau181和pTau217在SIMOA HD-X平台上进行测量。血浆 pTau217 无论是单独测定（ROC AUC = 0.94，95% CI：[0.88-1.00]），还是与 Aβ42 的比值（ROC AUC = 0.98，95% CI：[0.94-1.00]），在确定队列中的 CSF 生物标记物状态方面都表现出色。这项研究为巴西当地验证和采用痴呆症生物标志物迈出了第一步。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nature Communications Biological Science Disciplines-

CiteScore

24.90

自引率

2.40%

发文量

6928

审稿时长

3.7 months

期刊介绍： Nature Communications, an open-access journal, publishes high-quality research spanning all areas of the natural sciences. Papers featured in the journal showcase significant advances relevant to specialists in each respective field. With a 2-year impact factor of 16.6 (2022) and a median time of 8 days from submission to the first editorial decision, Nature Communications is committed to rapid dissemination of research findings. As a multidisciplinary journal, it welcomes contributions from biological, health, physical, chemical, Earth, social, mathematical, applied, and engineering sciences, aiming to highlight important breakthroughs within each domain.